HAVCR2 and lung carcinoma: Although we report no benefit in the EGFR TL mouse model of concurrent PD-1 plus TIM-3 blockade, we would caution against extrapolation of this result to human lung cancer given that this model expresses scant TIM-3 before PD-1 treatment and develops neutralizing antibodies to therapy which should not be the case in humans treated with humanized therapeutic antibodies.